The Ad5-TRAIL gene therapy for prostate cancer research trial is a Phase I study designed to test the optimal dosage at which the therapeutic agent can safely be given to patients.
The clinical study is being co-led by Thomas Griffith, Ph.D., an associate professor in the Department of Urology, and Richard Williams, M.D., the Rubin H. Flocks Chair in Urology and professor and head of the UI Department of Urology.
"This is the first use of this type of anti-cancer agent which was developed at the University of Iowa. This new gene therapy may help us successfully manage patients with high-risk prostate cancer," Griffith said. "Ideally, we hope to be able to say at the conclusion of this trial that this novel agent is safe and performs as intended by causing the death of prostate tumor cells with no harm to normal cells. However, being at the initial stages of the trial, it is premature to make any claims until the data is analyzed."
Researchers injected the investigational therapeutic into the cancerous prostates of three patients. Then, following a 10-day waiting period, surgeons removed the prostates and are evaluating the results.
"The preliminary results appear promising," Williams said. "The patients have tolerated the treatment without any serious side effects, which we hope will permit us to proceed with the research process."
Investigators plan to enroll up to 12 additional participants in the Phase I segment of the study.
"While the vaccine is not intended to be curative at this stage, the role of the research participants is critically important to what is truly a team effort. Without the involvement of our patients, we could not succeed," said Timothy Ratliff, Ph.D., the Anderson-Hebbeln Professor of Urology, and co-investigator in the study.
Funding for this trial has come from the following sources or agencies:
-- Roy J. Carver Charitable Trust - funds for preparing the clinical-grade virus;
-- Alliance for Cancer Gene Therapy - preclinical studies;
-- Holden Comprehensive Cancer Center at the UI - preclinical studies and protocol development;
-- U.S. Department of Defense - protocol development and clinical trial;
-- National Institutes of Health - clinical trial and Gelfoam studies.
To create the vaccine, the team used a virus that causes the common cold, but which has been engineered to be non-replicative in humans. The disabled virus, known as an adenovirus, can then be used as a vector, or carrier, of other genes that researchers insert into the virus.
The UI researchers say it will take several years before the treatment could be approved and come into general use, even if it is shown to be effective.
Other UI investigators involved in the study include:
Fadi Joudi, M.D.; Badrinath R. Konety, M.D.; Michael B. Cohen, M.D.; Brian K. Link, M.D.; Barbara Ziegler, program assistant; Tammy Madsen, physician assistant; and Carlene A. Etscheidt, clinical research coordinator.
Prostate cancer is the third-leading cause of death among men in the United States. African-American males are at a higher risk for the disease than other men.
Holden Comprehensive Cancer Center at the UI is Iowa's only National Cancer Institute (NCI)-designated comprehensive cancer center. NCI-designated comprehensive cancer centers are recognized as the leaders in developing new approaches to cancer prevention and cancer care, conducting leading edge research and educating the public about cancer.
STORY SOURCE: Joint Office for Marketing and Communications, University of Iowa Health Care, 200 Hawkins Drive, Room E110 GH, Iowa City, Iowa 52242-1009
MEDIA CONTACT: Tom Moore, 319-356-3945, firstname.lastname@example.org.
Tom Moore | EurekAlert!
Penn study identifies new malaria parasites in wild bonobos
21.11.2017 | University of Pennsylvania School of Medicine
NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures
17.11.2017 | National Institute of Standards and Technology (NIST)
The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.
Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....
The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.
Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...
Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.
That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...
Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.
During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....
The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.
Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...
15.11.2017 | Event News
15.11.2017 | Event News
30.10.2017 | Event News
21.11.2017 | Physics and Astronomy
21.11.2017 | Physics and Astronomy
21.11.2017 | Life Sciences